CDKN2B and glioblastoma: Patients with IDH1/2-wildtype glioblastomas harboring CDKN2B, EGFR, and TERT promoter mutations who underwent GTR were associated with improved OS when compared to other EOR in the FDR-adjusted analysis (Supplementary Table 3).